Trial Profile
A pilot, multicenter, open-label, one-group study to explore the efficacy, tolerability and safety of 15 mg TV-5010 administered once weekly in subjects with relapsing-remitting multiple sclerosis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Oct 2012
Price :
$35
*
At a glance
- Drugs TV 5010 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Teva Italy
- 17 May 2011 New trial record